News Daily News Women Less Likely Than Men to Experience SCD During Sports Michael O'Riordan December 21, 2021
News Features World-wise: As In-Person Meetings Resume, Global Voices Hope to Be Heard Shelley Wood December 13, 2021
News Daily News Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF L.A. McKeown December 07, 2021
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Daily News As Amyloidosis Field Explodes, Physicians Need to Spot and Treat Todd Neale October 20, 2021
News Daily News Higher CV Mortality Among More Socially Vulnerable US Adults Yael L. Maxwell October 20, 2021
News Features Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle Shelley Wood October 08, 2021
News Daily News FDA Investigating Possible Sex Differences in LAAO Outcomes Todd Neale September 27, 2021
News Daily News Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label Todd Neale September 20, 2021
News Daily News CMS Pays More to Male Cardiologists, but the Reasons Why Are Murky Michael O'Riordan September 10, 2021
News Daily News From Excess Amputations to Postpregnancy HF, Studies Shine Light on Racial Divide L.A. McKeown September 06, 2021
News Daily News Retracted Over Fraud Concerns, Surgisphere ACE/ARB Study Still Gets Cited Michael O'Riordan August 03, 2021
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Conference News ACC 2021 PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI L.A. McKeown May 15, 2021
News Daily News Women’s Risk for CVD Seen at Lower BP Thresholds Than Men L.A. McKeown February 24, 2021
News Daily News New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF Todd Neale February 16, 2021
News Daily News Despite COVID-19, Heart Disease Remains Top US Killer: AHA Michael O'Riordan January 28, 2021